Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Marcela Maus MD, PhD

Marcela V. Maus MD, PhD

Associate Professor, Harvard Medical School; Paula O’Keefe Chair in Oncology and Director of Cellular Immunotherapy, Massachusetts General Hospital Cancer Center, Boston, Massachusetts

Marcela Maus, MD, PhD, is currently an Associate Professor at Harvard Medical School, the Paula O’Keefe Chair in Oncology and Director of Cellular Immunotherapy at Massachusetts General Hospital (MGH) Cancer Center, and an Attending Physician in the Hematopoietic Cell Transplant and Cell Therapy division of Oncology at MGH. She is an Associate Member of the Broad Institute of Harvard and MIT, and an Associate Member of the Ragon Institute of MGH, MIT, and Harvard.

Dr. Maus is internationally known for her work as a translational physician-scientist in the field of immunology, particularly as it relates to T-cell immunotherapies and cellular therapies in the treatment of cancer. Her laboratory focuses on the biology of human T cell activation, costimulation, and memory, and on the application of human T cell therapies to human disease, including forward and reverse translation of engineered T cell therapies in early-phase clinical trials. She has authored over 170 papers indexed in Pubmed and holds multiple NIH R01 grants and several Investigational New Drug Applications (IND’s).

Dr. Maus completed undergraduate studies at Massachusetts Institute of Technology (MIT) and holds graduate degrees (MD, PhD) from University of Pennsylvania. Dr. Maus trained in internal medicine at University of Pennsylvania and in hematology and medical oncology at Memorial Sloan Kettering Cancer Center. She also serves on several scientific and clinical advisory boards for the biotechnology industry as well as external academic medical centers.


Dr. Maus reports the following:

  • MVM is an inventor on patents related to adoptive cell therapies, held by Massachusetts General Hospital (some licensed to Promab) and University of Pennsylvania (some licensed to Novartis).
  • MVM receives Grant/Research support from: Kite Pharma, Moderna
  • MVM has served as a consultant for multiple companies involved in cell therapies. 
  • MVM holds Equity in 2SeventyBio, A2Bio, Affyimmune, Cargo, Century Therapeutics, Neximmune, Oncternal, and TCR2
  • Board of Directors: 2Seventy Bio
  • Speaker’s Bureau : none
  • MVM has been or is a Consultant for : A2Bio (SAB), Adaptimmune, Agenus/Mink Therapeutics, Allogene, Arcellx, Astellas, AstraZeneca, Atara, BMS, Cabaletta Bio (SAB), Cargo (SAB), CRISPR therapeutics, In8bio (SAB), Intellia, GSK, Kite Pharma, Maxyte (SAB), Neximmune, Novartis, Oncternal, Sanofi, Sobi, Synthekine, TCR2 (SAB), and Tmunity